<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545243</url>
  </required_header>
  <id_info>
    <org_study_id>S60984/60953</org_study_id>
    <nct_id>NCT03545243</nct_id>
  </id_info>
  <brief_title>PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia</brief_title>
  <official_title>Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective interventional study of the effect of PPI on the duodenal microbiome in healthy&#xD;
      volunteers and functional dyspepsia patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPIs are the first-line therapy in functional dyspepsia (FD) but frequently (over-)prescribed&#xD;
      with potential adverse events, especially in the long term. As C. difficile and CAP are&#xD;
      important causes of morbidity, mortality and healthcare costs, it is important to study the&#xD;
      underlying mechanisms of PPI-induced dysbiosis.&#xD;
&#xD;
      In this prospective interventional study, study procedures will be performed at inclusion&#xD;
      (1), after a baseline period of 4 weeks (2) and after treatment with Pantoprazole (Pantomed®)&#xD;
      40mg once daily during 4 weeks (3) in healthy volunteers and FD patients. In addition, study&#xD;
      procedures will be performed at inclusion (1) and after PPI-withdrawal for 8 weeks in&#xD;
      refractory FD patients.&#xD;
&#xD;
      The investigators aim to assess alterations of the duodenal (mucosa-associated and luminal)&#xD;
      microbiome with PPI therapy and to correlate changes in the duodenal microbiota with oral and&#xD;
      fecal microbiota, bile acids, intestinal permeability and histology and biochemical&#xD;
      variables.&#xD;
&#xD;
      The results from this study will help to unravel the onset and extent of dysbiosis and&#xD;
      provide additional arguments not to prescribe or continue PPI without clear clinical&#xD;
      indications, especially in cases where alternative regimens may be available or the benefits&#xD;
      of PPI are uncertain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">March 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective interventional study with study procedures at inclusion, after a baseline period of 4 weeks and Pantoprazole therapy for 4 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microbiota composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in microbiota composition in the duodenum (lumen and mucosa) and feces</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mucosal inflammation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in mucosal inflammation (using immunohistochemistry) of the duodenum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mucosal permeability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in mucosal permeability (using ussing chambers) of the duodenum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bile acid composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in bile acid composition in the duodenum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Dysbiosis</condition>
  <arm_group>
    <arm_group_label>Pantoprazole 40mg in healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Peroral Pantoprazole 40mg once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole 40mg in functional dyspepsia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Peroral Pantoprazole 40mg once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI-withdrawal in functional dyspepsia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>no PPI for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40mg</intervention_name>
    <description>Peroral Pantoprazole 40mg once daily during 28 days</description>
    <arm_group_label>Pantoprazole 40mg in functional dyspepsia</arm_group_label>
    <arm_group_label>Pantoprazole 40mg in healthy volunteers</arm_group_label>
    <other_name>Pantomed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PPI withdrawal</intervention_name>
    <description>PPI withdrawal for 8 weeks</description>
    <arm_group_label>PPI-withdrawal in functional dyspepsia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged between 18 and 64 years inclusive&#xD;
&#xD;
          -  Male or female (not pregnant or lactating and using contraception or postmenopausal)&#xD;
&#xD;
          -  Normal bowel habits (defecation once every 3 days up to 3 times a day)&#xD;
&#xD;
          -  Witnessed written informed consent&#xD;
&#xD;
          -  Access to home freezer (-18 to -20°C)&#xD;
&#xD;
          -  Capable to understand and comply with the study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active psychiatric symptoms (stable dose of single antidepressant allowed)&#xD;
&#xD;
          -  Use of acid suppressive drugs (before starting Pantomed), immunosuppressants or&#xD;
             antibiotics &lt;3 months before sampling&#xD;
&#xD;
          -  Use of drugs influencing stool consistency, NSAIDs, anti-allergy drugs, bile acid&#xD;
             sequestrants or ursodeoxycholic acid &lt;2 weeks before sampling&#xD;
&#xD;
          -  Use of prokinetics &lt;2 weeks before sampling (unless if ≤3/week)&#xD;
&#xD;
          -  History of major abdominal surgery, including cholecystectomy but not appendectomy or&#xD;
             splenectomy&#xD;
&#xD;
          -  Personal or family (first-degree relative) history of diabetes mellitus type 1, celiac&#xD;
             disease, inflammatory bowel disease, psoriasis, rheumatic or other auto-immune&#xD;
             diseases (including therapy)&#xD;
&#xD;
          -  Allergy or atopy (eczema, asthma and/or allergic rhinoconjunctivitis) (including&#xD;
             therapy)&#xD;
&#xD;
          -  Kidney, liver or coagulation disorders&#xD;
&#xD;
          -  Active coronary or peripheral artery disease&#xD;
&#xD;
          -  Diabetes mellitus type 2 (including therapy)&#xD;
&#xD;
          -  Active malignancy (including therapy)&#xD;
&#xD;
          -  Known HIV, HBV or HCV infection (including therapy)&#xD;
&#xD;
          -  Magnetizable objects (e.g. cochlear implants, neural stimulator, pacemaker, metal&#xD;
             fragments or implants) or claustrophobia (MRI safety criteria with additional consent&#xD;
             form, other procedures can still take place)&#xD;
&#xD;
          -  Significant alcohol use (&gt;10 units/weeks)&#xD;
&#xD;
          -  Any use of alcohol or smoking ≤2 days before sampling&#xD;
&#xD;
          -  Females who are pregnant or lactating, who are not using contraception and&#xD;
             premenopausal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Vanuytsel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>duodenum</keyword>
  <keyword>microbiome</keyword>
  <keyword>proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

